Otsuka Holdings Co.,Ltd.
NDA Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA RTOR Program
Earlier from Otsuka
- Notice regarding the status of share repurchases
- Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
- Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median PFS Benefit in Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation NSCLC
- Zipalertinib Plus Chemotherapy Meets Primary PFS Endpoint in Planned Interim Analysis of Phase 3 REZILIENT3 Trial